Back to the Top
The following message was posted to: PharmPK
With interest I followed discussions.
The efforts to procure preclinical ADME data are impressive and the
results obtained believed to be of importance for predicting human drug
actions and toxicology.
To those of you involved in drug distribution studies I have one question:
How do you identify sites of in vivo action, i.e. sites of specific
Information on in vivo sites of action is important. I have never seen
this question addressed and discussed in your exchange of
letters. Apparently, nobody seems to have any problems with that. Is
identification of in vivo sites of receptor binding a part of your ADME -
DISTRIBUTION studies and, if so, how do you do it? How much confidence do
you have in the results obtained with your approach?
Sites of specific tissue binding (not just blood-related or unspecific
tissue deposition) are these included in your reports, required, not
required? Walter E. Stumpf
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (email@example.com)